22ND CENTURY GROUP INC (XXII)
US90137F3010 - Common Stock
Overall XXII gets a fundamental rating of 2 out of 10. We evaluated XXII against 8 industry peers in the Tobacco industry. XXII may be in some trouble as it scores bad on both profitability and health. XXII is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
XXII had negative earnings in the past year.
In the past year XXII has reported a negative cash flow from operations.
In the past 5 years XXII always reported negative net income.
In the past 5 years XXII always reported negative operating cash flow.
1.2 Ratios
XXII's Return On Assets of -216.65% is on the low side compared to the rest of the industry. XXII is outperformed by 87.50% of its industry peers.
XXII has a Return On Equity of -1633.47%. This is in the lower half of the industry: XXII underperforms 62.50% of its industry peers.
The Return On Invested Capital of XXII (306.57%) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -216.65% | ||
| ROE | -1633.47% | ||
| ROIC | 306.57% |
ROA(3y)-214.42%
ROA(5y)-143.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XXII's Operating Margin of 1896.54% is amongst the best of the industry. XXII outperforms 100.00% of its industry peers.
The Profit Margin and Gross Margin are not available for XXII so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1896.54% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XXII has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for XXII has been increased compared to 1 year ago.
XXII has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XXII is higher compared to a year ago.
2.2 Solvency
XXII has an Altman-Z score of -8.86. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.86, XXII is doing worse than 87.50% of the companies in the same industry.
A Debt/Equity ratio of 1.59 is on the high side and indicates that XXII has dependencies on debt financing.
With a Debt to Equity ratio value of 1.59, XXII is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.86 |
ROIC/WACC34.03
WACC9.01%
2.3 Liquidity
A Current Ratio of 1.09 indicates that XXII should not have too much problems paying its short term obligations.
XXII has a Current ratio of 1.09. This is comparable to the rest of the industry: XXII outperforms 50.00% of its industry peers.
XXII has a Quick Ratio of 1.09. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
With a decent Quick ratio value of 0.93, XXII is doing good in the industry, outperforming 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 0.93 |
3. Growth
3.1 Past
The earnings per share for XXII have decreased strongly by -76.90% in the last year.
Looking at the last year, XXII shows a very negative growth in Revenue. The Revenue has decreased by -94.97% in the last year.
XXII shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.03% yearly.
EPS 1Y (TTM)-76.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.09%
Revenue 1Y (TTM)-94.97%
Revenue growth 3Y4.64%
Revenue growth 5Y4.03%
Sales Q2Q%-66.62%
3.2 Future
The Earnings Per Share is expected to grow by 36.71% on average over the next years. This is a very strong growth
XXII is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -34.43% yearly.
EPS Next Y82.92%
EPS Next 2Y36.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-58.25%
Revenue Next 2Y-34.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XXII. In the last year negative earnings were reported.
Also next year XXII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
XXII's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XXII is cheaper than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 4.95 |
4.3 Compensation for Growth
XXII's earnings are expected to grow with 36.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for XXII!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22ND CENTURY GROUP INC
NASDAQ:XXII (12/20/2024, 8:00:02 PM)
After market: 5.03 +0.08 (+1.62%)4.95
+0.22 (+4.65%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)
Earnings (Next)
Inst Owners0.75%
Inst Owner Change1793.77%
Ins Owners21.41%
Ins Owner Change0.18%
Market Cap229.48M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-18.45%
Min Revenue beat(2)-31.87%
Max Revenue beat(2)-5.03%
Revenue beat(4)0
Avg Revenue beat(4)-33.68%
Min Revenue beat(4)-61.52%
Max Revenue beat(4)-5.03%
Revenue beat(8)1
Avg Revenue beat(8)-31.25%
Revenue beat(12)2
Avg Revenue beat(12)-21.11%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 95.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 66.1 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.95 |
EPS(TTM)-118.88
EYN/A
EPS(NY)-15.57
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.05
BVpS0.07
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -216.65% | ||
| ROE | -1633.47% | ||
| ROCE | 388.07% | ||
| ROIC | 306.57% | ||
| ROICexc | 562.5% | ||
| ROICexgc | 5347.47% | ||
| OM | 1896.54% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-214.42%
ROA(5y)-143.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.12 | ||
| Cap/Depr | 106.84% | ||
| Cap/Sales | 57.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.09 | ||
| Quick Ratio | 0.93 | ||
| Altman-Z | -8.86 |
F-Score2
WACC9.01%
ROIC/WACC34.03
Cap/Depr(3y)127.65%
Cap/Depr(5y)92.29%
Cap/Sales(3y)10.61%
Cap/Sales(5y)7.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.09%
EPS Next Y82.92%
EPS Next 2Y36.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-94.97%
Revenue growth 3Y4.64%
Revenue growth 5Y4.03%
Sales Q2Q%-66.62%
Revenue Next Year-58.25%
Revenue Next 2Y-34.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y167.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.43%
OCF growth 3YN/A
OCF growth 5YN/A